Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» bimagrumab
bimagrumab
Hungry for more, Lilly tops off weight loss pipeline with $1.9B deal to acquire Versanis
Fierce Biotech
Fri, 07/14/23 - 10:10 am
Eli Lilly
M&A
obesity
Versanis
bimagrumab
Versanis Bio unveils $70M and a Novartis drug ready for Phase 2 test in obesity
MedCity News
Tue, 08/31/21 - 10:05 pm
Versanis Bio
Novartis
bimagrumab
clinical trials
funding
obesity
What Does The FDA's Breakthrough Designation Mean For Investors?
Seeking Alpha
Mon, 08/26/13 - 01:28 pm
FDA
breakthrough therapies
AbbVie
Alexion
Ariad Pharmaceuticals
Biomarin
Bristol-Myers Squibb
SynaGeva BioPharma
GSK
JNJ
Merck
Novartis
Pharmacyclics
Pfizer
Vertex Pharmaceuticals
daratumumab
ibrutinib
Kalydeco
lambrolizumab
palbociclib
LDK378
SD-101
obinutuzumab
serelaxin
asfotase alfa
bimagrumab
drisapersen
sebelipase alfa
